



Strategies to safely rule out pulmonary embolism in COVID-19 outpatients: a multicenter retrospective study

Guillaume Chassagnon, Mostafa El Hajjam, Samia Boussouar, Marie-Pierre Revel, Ralph Khoury, Benoît Ghaye, Sebastien Bommart, Mathieu Lederlin, Stephane Tran Ba, Constance de Margerie-Mellon, et al.

► To cite this version:

Guillaume Chassagnon, Mostafa El Hajjam, Samia Boussouar, Marie-Pierre Revel, Ralph Khoury, et al.. Strategies to safely rule out pulmonary embolism in COVID-19 outpatients: a multicenter retrospective study. *European Radiology*, 2023, 33 (8), pp.5540-5548. 10.1007/s00330-023-09475-6 . hal-04249768v2

HAL Id: hal-04249768

<https://hal.science/hal-04249768v2>

Submitted on 5 Feb 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Strategies to safely rule out pulmonary embolism in COVID-19 outpatients: a multicenter retrospective study

Guillaume Chassagnon¹, Mostafa El Hajjam², Samia Boussouar³, Marie-Pierre Revel⁴, Ralph Khoury⁵, Benoît Ghaye⁶, Sebastien Bommart⁷, Mathieu Lederlin⁸, Stephane Tran Ba⁹, Constance De Margerie-Mellon¹⁰, Laure Fournier¹¹, Lucie Cassagnes¹², Mickael Ohana¹³, Carole Jalaber¹⁴, Gael Dournes¹⁵, Nicolas Cazeneuve¹⁶, Gilbert Ferretti¹⁷, Pauline Talabard², Victoria Donciu¹⁸, Emma Canniff⁴, Marie-Pierre Debray⁵, Bernard Crutzen⁶, Jeremy Charriot¹⁹, Valentin Rabeau⁸, Philippe Khafagy⁹, Richard Chocron²⁰, Ian Leonard Lorant¹³, Loic Metairy¹⁶, Lea Ruez-Lantuejoul¹⁷, Sébastien Beaune²¹, Pierre Hausfater²², Jennifer Truchot²³, Antoine Khalil⁵, Andrea Penaloza²⁴, Thibaut Affole⁸, Pierre-Yves Brillet²⁵, Catherine Roy¹³, Julien Pucheux¹⁶, Jordan Zbili⁸, Olivier Sanchez²⁶, Raphael Porcher²⁷; on the behalf of the French Society of Thoracic Imaging

¹ Radiology Department, Hôpital Cochin, AP-HP, Université Paris Cité, 27 Rue du Faubourg Saint-Jacques, 75014, Paris, France. guillaume.chassagnon@aphp.fr.

² Radiology Department, Hôpital Ambroise Paré, AP-HP, Université Paris Saclay, 9 Av. Charles de Gaulle, 92100, Boulogne-Billancourt, France.

³ Cardiothoracic Imaging Unit, Hôpital Pitié-Salpêtrière, AP-HP, Sorbonne Université Laboratoire d'imagerie Biomédicale, INSERM, ICAN Institute of Cardiometabolism and Nutrition, 47-83 Boulevard de L'Hôpital, 75013, Paris, France.

⁴ Radiology Department, Hôpital Cochin, AP-HP, Université Paris Cité, 27 Rue du Faubourg Saint-Jacques, 75014, Paris, France.

⁵ Radiology Department, Hôpital Bichat, AP-HP, Université Paris Cité, 46 Rue Henri Huchard, 75018, Paris, France.

⁶ Radiology Department, Cliniques Universitaires Saint-Luc, 10 Avenue Hippocrate, 1200, Bruxelles, Belgium.

⁷ Radiology Department, Hôpital Arnaud de Villeneuve, PHYMEDEXP - INSERM U1046 - CNRS UMR 9214, Université de Montpellier, 371 Avenue Doyen Gaston Giraud, 34090, Montpellier, France.

⁸ Radiology Department, Hôpital Pontchaillou, CHU Rennes, Université de Rennes, 2 Rue Henri Le Guilloux, 35000, Rennes, France.

⁹ Radiology Department, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, 125 Rue de Stalingrad, 93000, Bobigny, France.

¹⁰ Radiology Department, Hôpital Saint-Louis, AP-HP, Université Paris Cité, 1 Avenue Claude Vellefaux, 75010, Paris, France.

¹¹ Radiology Department, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, 20 Rue Leblanc, 75015, Paris, France.

¹² Radiology Department, CHU Gabriel Montpied, Institut Pascal, TGI, UMR6602 CNRS SIGMA UCA, Université Clermont Auvergne, 58 Rue Montalembert, 63000, Clermont-Ferrand, France.

¹³ Radiology Department, Nouvel Hôpital Civil, CHU de Strasbourg, Université de Strasbourg, 1 Place de L'Hôpital, 67000, Strasbourg, France.

¹⁴ Radiology Department, CHU Saint Etienne, Avenue Albert Raimond, 42270, Saint-Priest-en-Jarez, France.

¹⁵ Department of Cardio-Thoracic Imaging, Hôpital Haut-Lévêque, CHU de Bordeaux, Université de Bordeaux, INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, CIC 1401, 1 Avenue Magellan, 33600, Pessac, France.

¹⁶ Radiology Department, Hôpital Trousseau, CHU Tours, Avenue de La République, 37170, Chambray-Lès-Tours, France.

¹⁷ Radiology Department, CHU de Grenoble Alpes, Université Grenoble Alpes, avenue des Maquis du Grésivaudan, 38700 La Tronche, 38043, Grenoble, France.

¹⁸ Radiology Department, Hôpital Pitié Salpêtrière, AP-HP, Sorbonne Université 47-83 Boulevard de L'Hôpital, 75013, Paris, France.

¹⁹ Pulmonology Department, Hôpital Arnaud de Villeneuve, CHU Montpellier, 371 Avenue Doyen Gaston Giraud, 34090, Montpellier, France.

²⁰ Emergency Department, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, 20 Rue Leblanc, 75015, Paris, France.

²¹ Emergency Department, Hôpital Ambroise Paré, AP-HP, Université Paris Saclay, 9 Avenue Charles de Gaulle, 92100, Boulogne-Billancourt, France.

²² Emergency Department, Hôpital Pitié Salpêtrière, AP-HP, GRC-14 BIOSFAST Sorbonne Université, UMR INSERM 1166, IHU ICAN, Sorbonne Université, 47-83 Boulevard de L'Hôpital, 75013, Paris, France.

²³ Emergency Department, Hôpital Cochin, AP-HP, Université Paris Cité, 27 Rue du Faubourg Saint-Jacques, 75014, Paris, France.

²⁴ Services Des Urgences, Cliniques Universitaires Saint-Luc, 10 Avenue Hippocrate, 1200, Bruxelles, Belgium.

²⁵ Radiology Department, Hôpital Avicenne, AP-HP, UMR U1272 Hypoxie Et Poumon INSERM, Université Sorbonne Paris Nord, 125 Rue de Stalingrad, 93000, Bobigny, France.

²⁶ Pulmonology Department, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, 20 Rue Leblanc, 75015, Paris, France.

²⁷ Center for Clinical Epidemiology, Hôtel Dieu, AP-HP, Université Paris Cité, 1 Place du Parvis de, 75004, Paris, France.

Keywords:

COVID-19; Computed tomography angiography; Pulmonary embolism.

Abbreviations

AUC Area under the receiver operating characteristics curve; CI Confidence interval; CLPTP Clinical pretest probability; CRP C-reactive protein; CTPA Computed tomography pulmonary angiogram; ICU Intensive care unit; IQR Interquartile range; LDH Lactate dehydrogenase; PE Pulmonary embolism

E-mail

* Guillaume Chassagnon
guillaume.chassagnon@aphp.fr

Abstract

Objectives:

The objective was to define a safe strategy to exclude pulmonary embolism (PE) in COVID-19 outpatients, without performing CT pulmonary angiogram (CTPA).

Methods:

COVID-19 outpatients from 15 university hospitals who underwent a CTPA were retrospectively evaluated. D-Dimers, variables of the revised Geneva and Wells scores, as well as laboratory findings and clinical characteristics related to COVID-19 pneumonia, were collected. CTPA reports were reviewed for the presence of PE and the extent of COVID-19 disease. PE rule-out strategies were based solely on D-Dimer tests using different thresholds, the revised Geneva and Wells scores, and a COVID-19 PE prediction model built on our dataset were compared. The area under the receiver operating characteristics curve (AUC), failure rate, and efficiency were calculated.

Results:

In total, 1369 patients were included of whom 124 were PE positive (9.1%). Failure rate and efficiency of D-Dimer > 500 µg/l were 0.9% (95%CI, 0.2-4.8%) and 10.1% (8.5-11.9%), respectively, increasing to 1.0% (0.2-5.3%) and 16.4% (14.4-18.7%), respectively, for an age-adjusted D-Dimer level. D-dimer > 1000 µg/l led to an unacceptable failure rate to 8.1% (4.4-14.5%). The best performances of the revised Geneva and Wells scores were obtained using the age-adjusted D-Dimer level. They had the same failure rate of 1.0% (0.2-5.3%) for efficiency of 16.8% (14.7-19.1%), and 16.9% (14.8-19.2%) respectively. The developed COVID-19 PE prediction model had an AUC of 0.609 (0.594-0.623) with an efficiency of 20.5% (18.4-22.8%) when its failure was set to 0.8%.

Conclusions:

The strategy to safely exclude PE in COVID-19 outpatients should not differ from that used in non-COVID-19 patients. The added value of the COVID-19 PE prediction model is minor.

Key points:

- D-dimer level remains the most important predictor of pulmonary embolism in COVID-19 patients.
- The AUCs of the revised Geneva and Wells scores using an age-adjusted D-dimer threshold were 0.587 (95%CI, 0.572 to 0.603) and 0.588 (95%CI, 0.572 to 0.603).
- The AUC of COVID-19-specific strategy to rule out pulmonary embolism ranged from 0.513 (95%CI: 0.503 to 0.522) to 0.609 (95%CI: 0.594 to 0.623).

Introduction

Early during the first wave of the COVID-19 pandemic, there was awareness of an increased risk of pulmonary embolism in COVID-19 patients [1, 2]. However, the recommendation from the expert societies was not to perform CT pulmonary angiogram (CTPA) as a first-line imaging modality, but rather unenhanced CT in patients presenting with dyspnea and/or desaturation [3]. Most series reporting an increased incidence of PE were based on patients with severe disease admitted to intensive care units (ICU) [4]. A meta-analysis found a pooled incidence of 24.6% for PE in intensive care unit (ICU) patients compared to 10.5% in non-ICU patients [4]. In a series based on outpatients presenting to the emergency department (ED), the observed incidence was much lower than that of ICU patients. In a series where CTPA was systematically performed in all patients presenting to ED with suspected SARS-CoV-2 infection, the prevalence of PE was lower in COVID-19 patients in comparison to non-COVID-19 patients (5.7 vs. 8.5%) [5]. Similarly, in a large multicenter study, Freund et al did not report an increased risk of PE in COVID-19 patients presenting to the emergency department [6].

However, the reported increased risk of PE and the systematic dosage of D-dimers due to their important prognostic value, has led to an increase in CTPA referrals in COVID-19 patients as shown by the data from the French National Hospital Discharge database [7].

Conventional strategies to exclude PE without performing CTPA rely on a pre-test assessment of the clinical probability using a validated clinical decision rule, combined with D-dimer testing [8]. The most widely used and recommended clinical decision rules are the Wells [9] and the revised Geneva [10] scores. For D-Dimers, several strategies are available: a fixed threshold of 500 µg/L, an age-adjusted threshold, or a pretest probability-dependent threshold. However, most COVID-19 patients present with increased D-Dimer, due to the severity of inflammation [11]. Furthermore, clinical risk factors for PE such as a history of cancer or previous venous thromboembolism do not show the same predictive value in COVID-19 patients, resulting in inadequacy in the usual prediction rules for this population [12, 13]. Therefore, a strategy adapted to the COVID-19 context is lacking. The aim of this study was to use a large multicenter dataset to define a specific strategy to exclude PE in COVID-19 outpatients, without performing CTPA.

Methods

Study population

This study was conducted on behalf of the French Society of Thoracic Imaging. It received institutional review board approval with a waiver for patient consent (Ethical Review Committee for publications of the Cochin University Hospital (CLEP) (CLEP Decision N°: AAA-2020-08046)).

All adult outpatients who underwent a CTPA between February 1, 2020, and October 31, 2020, within 48 h of presentation at the ED of 15 university hospitals (14 in France and 1 in Belgium) were retrospectively evaluated. They were included if they had a positive RT-PCR

test within 48 h of the CTPA examination and a conclusive CTPA report. Missing data such as a D-Dimer level was not an exclusion criterion.

Analyzed parameters

Patient's charts were reviewed for demographic characteristics (age, sex), body temperature, heart rate, and pulse oximetry in the emergency department; body mass index; and other clinical characteristics to calculate the Wells score [9] and the revised Geneva score [10]. A history of previous deep vein thrombosis or PE, recent surgery or fracture of a lower limb within 1 month, and the presence of active malignancy or unilateral lower limb pain, or painful lower limb palpation with unilateral edema and hemoptysis were systematically assessed. Due to the retrospective design of the study, it was not possible to determine whether an alternative diagnosis was less likely than PE, and this criterion could not be evaluated for, when calculating the Wells score.

D-Dimer levels and laboratory data known to be associated with COVID-19 severity were collected, specifically C-reactive protein (CRP), lactate dehydrogenase (LDH), and lymphocyte and neutrophil counts. Clinical information such as symptom duration, fever during the few days prior to admission, body temperature, pulse oximetry, and oxygen flow rates was also collected.

Radiology reports were reviewed for the presence of PE as well as the extent of COVID-19 pneumonia. The extent of COVID-19 pneumonia was assessed using a 5-point scale (0%, < 25%, 25–50%, 50–75%, > 75%) [14, 15], using the structured report proposal from the French Society of Thoracic Imaging and the French Society of Radiology [16]. For all hospitalized patients presenting to the emergency department without a PE, hospital charts were reviewed for the occurrence of a secondary PE.

Patients whose CTPA was inconclusive for PE were excluded from the analysis when evaluating the performance of the different rule-out strategies. [IQR: 3.3 to 6.8]; $p < 0.001$, respectively). Patients with PE had symptoms for a longer period of time (8 days [IQR: 5 to 15] vs. 7 [IQR: 5 to 10]; $p = 0.0006$), their body temperature was lower (37.3 ± 0.9 °C vs. 37.7 ± 1.1 °C; $p < 0.0001$) and they were less febrile during the few days prior to admission (32.5% vs. 44.4%; $p = 0.012$).

Oxygen saturations, CRP, LDH, and the extent of COVID-19 pneumonia were not significantly different between the groups ($p > 0.05$ in Table 1).

Performance of conventional strategies to rule out PE

In our population, the AUCs of the revised Geneva and Wells scores were 0.550 (95% confidence interval (95%CI): 0.538 to 0.563%) and 0.551 (95%CI, 0.538 to 0.563), respectively, when using a fixed D-Dimer threshold of 500 µg/L (Table 2). Both strategies had the same high sensitivity of 99.1% (95%CI, 95.2 to 99.8%) and the same low failure rate of 0.9% (95%CI, 0.2 to 4.8%). However, they had a low specificity of 11% (95%CI, 9.2 to 13.0%) for the revised Geneva score and 11% (95%CI, 9.3 to 13.0%) for the Wells score. Their efficiency was 10.0% (95%CI, 8.5 to 11.9%) and 10.1% (95%CI, 8.5 to 11.9%), respectively. This means that their use would have prevented unnecessary CTPAs in 134 and 135 of the 1369 patients for the Revised Geneva and the Wells score, respectively; however, it would have resulted in one undiagnosed PE in each case.

The use of an age-adjusted D-dimer threshold increased the performance of both strategies (Table 2). The AUC of the revised Geneva and Wells score increased to 0.587 (95%CI, 0.572 to 0.603) and 0.588 (95%CI, 0.572 to 0.603).

Table 1 Participants characteristics

	No	All participants N=1369	PE* N=124	No PE N=1226	p
Age, mean (SD) years	1369	63.3 (16.4)	66.8 (16.4)	62.9 (16.3)	0.014
Female gender, no. (%)	1369	569 (41.6)	45 (36.3)	520 (42.4)	0.19
BMI (kg/m ²), no. (%)	744				0.34
< 25		247 (33.2)	16 (27.1)	224 (33.4)	
25–29.9		251 (33.7)	25 (42.4)	222 (33.1)	
> 29.9		246 (33.1)	18 (30.5)	224 (33.4)	
Previous DVT or PE, no. (%)	1364	97 (7.1)	15 (12.2)	80 (6.5)	0.026
Surgery or fracture (of lower limbs) within 1 month no. (%)	1366	17 (1.2)	2 (1.6)	15 (1.2)	0.66
Active malignant condition (active or cured < 1 y), no. (%)	1365	116 (8.5)	13 (10.6)	102 (8.3)	0.40
Hemoptysis, no. (%)	1366	20 (1.5)	5 (4.1)	15 (1.2)	0.030
Unilateral lower-limb pain, no. (%)	1366	32 (2.3)	16 (13.0)	16 (1.3)	<0.0001
Pain on lower-limb deep venous palpation, no. (%)	1234	27 (2.2)	11 (10.2)	16 (1.4)	<0.0001
Heart rate, mean (SD) bpm	1316	92.2 (17.7)	94.1 (18.3)	92.1 (17.7)	0.17
CRP, median (IQR) mg/L	1278	72 (30 to 130)	80 (36 to 131)	71 (30 to 129)	0.15
LDH, median (IQR) IU/L	591	352 (266 to 461)	363 (252 to 487)	351 (266 to 459)	0.48
D-Dimer, median (IQR) µg/L	1176	1100 (700 to 1900)	3830 (2000 to 4000)	1000 (700 to 1600)	<0.0001
Lymphocytes, median (IQR) G/L	1329	0.9 (0.7 to 1.4)	1.1 (0.7 to 1.7)	0.9 (0.7 to 1.3)	0.003
Neutrophil, median (IQR) G/L	1227	4.9 (3.4 to 7.0)	6.7 (5.0 to 9.4)	4.6 (3.3 to 6.8)	<0.0001
Symptom duration, median (IQR) days	1304	7 (5 to 10)	8 (5 to 15)	7 (5 to 10)	0.0006
Fever in previous days, no. (%)	1314	569 (43.3)	39 (32.5)	522 (44.4)	0.012
Body temperature, mean (SD) °C	1335	37.6 (1.0)	37.3 (0.9)	37.7 (1.1)	<0.0001
SpO ₂ , median (IQR) %	1233	94 (90 to 96)	94 (89 to 96)	94 (90 to 97)	0.36
Oxygen flow, median (IQR) L/min	1241	2.0 (0.0 to 4.0)	2.0 (0.0 to 4.2)	2.0 (0.0 to 4.0)	0.13
COVID-19 extension by CT-scan, no. (%)	1369				0.084
0%		80 (5.8)	8 (6.5)	70 (5.7)	
< 10%		247 (18.0)	32 (25.8)	213 (17.4)	
10–25%		438 (32.0)	36 (29.0)	398 (32.5)	
25–50%		381 (27.8)	26 (21.0)	348 (28.4)	
50–75%		170 (12.4)	14 (11.3)	153 (12.5)	
> 75%		53 (3.9)	8 (6.5)	44 (3.6)	

* 19 participants with uninterpretable CT-scan

The sensitivity of 99.0% (95%CI, 94.7 to 99.8%) for the revised Geneva score and 99.0% (95%CI, 94.7 to 99.8%) for the Wells score and the failure rate remained similar with the age-adjusted D-dimer threshold (1.0% (95%CI, 0.2 to 5.3%) for both scores), whereas the efficiency increased to 16.8% (95%CI, 14.7 to 19.1%) for the revised Geneva score and 16.9% (95%CI, 14.8 to 19.2%) for the Wells score. Using this D-Dimer threshold would have prevented unnecessary CTPAs for 226 and 227 patients for the revised Geneva and Wells scores, respectively.

We also evaluated the CPTP-adjusted D-dimer threshold with the revised Geneva and the Wells score. This increased their efficiency to 36.0% (95%CI, 33.4 to 38.7%) and 41.8% (95%CI, 39.1 to 44.6%), for the revised Geneva and Wells scores, respectively. However, this combination was associated with a marked increase in failure rate: 7.1% (95%CI, 3.7 to 13.3%) and 8.1% (95%CI, 4.4 to 14.5%) for the revised Geneva and Wells scores, respectively. This CPTP adjusted D-dimer threshold would have avoided 477 and 555 unnecessary CTPAs; however, it would have missed 9 and 10 PEs, using the revised Geneva or Wells score, respectively.

Table 2 Performance of diagnostic strategies

Diagnostic strategy	AUC	Sensitivity (%)	Specificity (%)	NPV (%)	Failure rate (%)	Efficacy (%)
RGS score						
Fixed D-dimer	0.550 (0.538–0.563)	99.1 (95.2–99.8)	11.0 (9.2–13.0)	99.2 (95.6–99.9)	0.9 (0.2–4.8)	10.0 (8.5–11.9)
Age-adjusted D-dimer	0.587 (0.572–0.603)	99.0 (94.7–99.8)	18.4 (16.1–20.9)	99.5 (97.0–99.9)	1.0 (0.2–5.3)	16.8 (14.7–19.1)
CTIP-adjusted D-dimer	0.659 (0.631–0.686)	92.9 (86.7–96.3)	38.9 (36.1–41.8)	98.2 (96.5–99.1)	7.1 (3.7–13.3)	36.0 (33.4–38.7)
Wells score						
Fixed D-dimer	0.551 (0.538–0.563)	99.1 (95.2–99.8)	11.0 (9.3–13.0)	99.2 (95.6–99.9)	0.9 (0.2–4.8)	10.1 (8.5–11.9)
Age-adjusted D-dimer	0.588 (0.572–0.603)	99.0 (94.7–99.8)	18.5 (16.3–21.0)	99.5 (97.0–99.9)	1.0 (0.2–5.3)	16.9 (14.8–19.2)
CTIP-adjusted D-dimer	0.686 (0.657–0.715)	91.9 (85.5–95.6)	45.2 (42.3–48.2)	98.2 (96.7–99.0)	8.1 (4.4–14.5)	41.8 (39.1–44.6)
D-dimer						
> 500 µg/L	0.551 (0.538–0.563)	99.1 (95.2–99.8)	11.0 (9.3–13.0)	99.2 (95.6–99.9)	0.9 (0.2–4.8)	10.1 (8.5–11.9)
> Age × 10 µg/L*	0.585 (0.570–0.600)	99.0 (94.7–99.8)	18.0 (15.7–20.4)	99.5 (97.0–99.9)	1.0 (0.2–5.3)	16.4 (14.4–18.7)
> 1000 µg/L	0.687 (0.658–0.716)	91.9 (85.5–95.6)	45.5 (42.5–48.4)	98.2 (96.7–99.0)	8.1 (4.4–14.5)	42.0 (39.3–44.8)
Prediction models						
Firth regression	0.532 (0.522–0.543)	99.2** (—)	7.3 (5.9–8.8)	98.9 (94.0–99.9)	0.8** (—)	6.7 (5.5–8.1)
Firth regression, weighted	0.609 (0.594–0.623)	99.2** (—)	22.5 (20.3–24.9)	99.6 (98.0–100.0)	0.8** (—)	20.5 (18.4–22.8)
Gradient boosting	0.543 (0.532–0.555)	99.2** (—)	9.5 (7.9–11.2)	99.1 (95.3–100.0)	0.8** (—)	8.7 (7.3–10.3)
Gradient boosting, weighted	0.513 (0.503–0.522)	99.2** (—)	3.3 (2.5–4.5)	97.6 (87.7–99.9)	0.8** (—)	3.1 (2.3–4.2)

* Or 500 µg/L if age < 50 y

** Threshold to obtain a sensitivity as close as possible to, but not lower than, 99.0%

Despite the significant association between the risk of PE and several items of data from the revised Geneva and Wells scores, the performance of the conventional diagnostic strategies was on par with that of D-Dimer alone. Indeed, the AUC, sensitivity, failure rate, and efficiency of a D-Dimer level < 500 µg/L to rule out PE were 0.551 (95%CI, 0.538 to 0.563), 99.1% (95%CI, 95.2 to 99.8%), 0.9% (95%CI, 0.2 to 4.8%), and 10.1% (95%CI, 8.5 to 11.9%), respectively. Similarly, the AUC, sensitivity, failure rate, and efficiency of an age-adjusted D-Dimer threshold were 0.585 (95%CI, 0.570 to 0.600), 99.0% (95%CI, 94.7 to 99.8%), 1.0% (95%CI, 0.2 to 5.3%), and 16.4% (95%CI, 14.4 to 18.7%). Thus, using D-dimers alone to rule out PE would have led to 135 CTPAs not being performed resulting in one undiagnosed PE, for a fixed threshold of 500 µg/L and 220 CTPAs not being performed resulting in one undiagnosed PE for an age-adjusted threshold. Increasing the D-dimer threshold to 1000 µg/L increased the AUC to 0.687 (95%CI, 0.658 to 0.716) but decreased the sensitivity to 91.9% (95%CI, 85.5 to 95.6%) and increased the failure rate to 8.1% (95%CI, 4.4 to 14.5%), meaning that 10 Pes would have been missed whereas 557 CTPAs would have been avoided.

Performance of a COVID-19-specific strategy to rule out PE

Two machine learning methods, each with and without weighting, were used to develop a COVID-19 pneumonia specific rule-out strategy (Supplementary Table 1 and Supplementary Fig. 1). AUCs were in the same range as those of the revised Geneva and the Wells scores, ranging from 0.513 (95%CI: 0.503 to 0.522) to 0.609 (95%CI: 0.594 to 0.623) (Table 2, Fig. 2). To obtain a strategy as safe as that of the revised Geneva and the Wells score, we set the models to have a failure rate close to 1%, meaning a sensitivity of 99%. Thus, all models had a failure rate of 0.8% and efficacy ranging from 3.1 to 20.5%. These scores would have prevented 41 out of 276 CTPAs resulting in one undiagnosed PE. Evaluating the influence of variables on the models showed that, once again, the D-dimer had a prominent role (Supplementary Fig. 2).




Fig. 2 Receiver operating characteristics curves. The dark blue curve, the points, and numbers indicate the performance at selected thresholds in $\mu\text{g/L}$ for D-dimer. For data-driven models, the ROC curves and AUCs are corrected for optimism

Discussion

In this study, we showed that conventional strategies to rule out PE can also be applied in the setting of COVID-19 and that a dedicated strategy does not perform better. Although COVID-19 is associated with an increase in D-dimers, we observed that the D-dimer level remains the most important predictor of PE. The AUCs of strategies based on D-dimers alone were only marginally improved by the addition of other variables. This demonstrates that, although the specificity of a high D-dimer value may be compromised by the SARS-Cov-2 infection, D-dimers should remain a major biomarker in the rule-out strategy for PE, even if this results in more CTPAs being performed. Several authors have suggested tailoring the D-dimer level threshold to the specific context of COVID-19. Levels of 1000, 2000, 3000, or even higher than 6000 $\mu\text{g/L}$ have been suggested to better identify patients with PE [25–28].

However, we found a D-Dimer threshold of 1000 $\mu\text{g/L}$ led to an unacceptable failure rate of 8.1%, much higher than the failure rate of 2% reported by Revel et al [7]. Therefore, increasing the D-Dimer threshold in the specific setting of COVID-19 pneumonia should be avoided. The use of a CPTP-adjusted D-dimer threshold in combination with the revised Geneva and the Wells score also led to an unacceptable increase in the failure rate.

In our study, the age-adjusted D-dimer threshold happened to be the best choice. The failure rates of rule out strategies based on D-dimers alone or D-dimers combined with pre-test clinical probability scores were close to those reported by Stals et al in their meta-analysis on the safety and efficiency of diagnostic strategies for ruling out PE in the general population, with 0.36 to 1.1% depending on the use of fixed or age-adjusted D-dimer thresholds [8]. These failure rates are lower than the maximum acceptable failure rate according to the International Society on Thrombosis and Haemostasis (ISTH) recommendation [29]. Revel et al recently reported similar failure rates of 1.3% for a fixed D-Dimer threshold of 500 $\mu\text{g/L}$ and 2.2% for an age-adjusted threshold in a cohort of 781 COVID-19 from the COVID

database of Parisian public hospitals [7]. While the failure rates were comparable to those observed in the general population, the efficiency was significantly lower than the 26 to 37% reported by Stals et al for the same strategies applied to the general population. This explains the increase in the number of CTPAs performed in COVID-19 patients [8].

Among the clinical variables routinely evaluated in order to estimate the risk of PE in the general population, some were associated with a significantly higher risk of PE such as hemoptysis, a unilateral lower limb pain or painful palpation, a history of deep vein thrombosis or PE, surgery or fracture of lower limb within the preceding month. Most pulmonary thrombi are related to deep vein thrombosis embolization. However, in the context of COVID-19, the smaller size and more frequent peripheral location of pulmonary emboli suggest that some pulmonary emboli might be related to in situ thrombosis [30]. However, the association between the clinical manifestations of deep vein thrombosis and the risk of PE in our study illustrates the involvement of a thromboembolic mechanism in COVID-19. This is consistent with the increased frequency of deep vein thrombosis in COVID-19 patients. In a meta-analysis, Jimenez et al reported a pooled incidence of 12.1% for deep vein thrombosis versus 7.8% for PE in hospitalized COVID-19 patients [31].

Several variables commonly assessed in COVID-19 pneumonia correlated with an increased risk of PE. Lymphocyte and neutrophil counts were higher in patients with PE. This is in agreement with Galland et al who found that a white blood cell count $> 12\text{G/L}$ was associated with an increased risk of PE in COVID-19 patients in a multivariate analysis [27]. Thoreau et al also showed that a neutrophil count $> 7\text{ G/L}$ was a biomarker of PE risk [32]. Similarly to Fang et al, we did not find a difference in the extent of COVID-19 pneumonia between patients with and without PE [33].

Our best-performing model combining D-dimer and other markers had an AUC of 0.532 and its use would have avoided 276 CTPAs with the same safety as that of the revised Geneva and Wells score. However, a bias of our proposed COVID-19-specific strategy is that it was developed and tested on the same dataset, and validation on an external dataset is missing. Despite the use of statistical methods to address overoptimism, our proposed COVID-19-specific model might have been favored over conventional strategies due to the fact that it was developed and tested on our dataset.

Lastly, our study only included patients with a suspicion of PE which led to a CTPA being performed. Our results do not apply to COVID-19 patients with an isolated increase in the D-Dimer and who are not clinically suspected of having PE. An elevated D-Dimer level itself should not lead to a CTPA being performed.

Our study has some limitations. Firstly, this is a retrospective study and the indication for CTPA was at the discretion of the referring physicians in each center. It is possible that some patients who did not undergo a CTPA had PE, and therefore, the true incidence of PE in this COVID-19 population cannot be calculated. Also, an unknown proportion of COVID-19 patients suspected of having a PE may not have undergone a CTPA due to a negative D-Dimer. Since these true negatives were not taken into account, the performance of the different rule out strategies may have been underestimated. Despite this potential selection bias, the D-Dimer remained the main criterion to exclude PE and was selected in the COVID-19-specific model. In addition, only parameters routinely assessed in the setting of patients with COVID-19 pneumonia could be analyzed, and there were missing data relating

to the likelihood of an alternative diagnosis of PE, which could not be assessed retrospectively and was therefore considered negative in all patients.

In conclusion, our study shows that the strategy to safely exclude PE in COVID-19 patients at the emergency department should not differ from that used in non-COVID-19 patients and could be based on D-Dimers alone, by using an age-adjusted D-dimer threshold. COVID-19-specific strategies to exclude PE as the one which was developed, are more complex and only result in a small decrease of CTPAs being performed.

Declarations

Guarantor The scientific guarantor of this publication is GC.

Conflict of interest

The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.

Statistics and biometry

RP has significant statistical expertise. Informed consent Written informed consent was waived by the Institutional Review Board.

Ethical approval

Institutional Review Board approval was obtained.

Methodology

- Retrospective
- diagnostic
- multicenter study

References

1. Bompard F, Monnier H, Saab I, et al. Pulmonary embolism in patients with COVID-19 pneumonia. Eur Respir J. 2020;56:2001365. doi: 10.1183/13993003.01365-2020. - [DOI](#) - [PMC](#) - [PubMed](#)
2. Le Berre A, Marteau V, Emmerich J, Zins M. Concomitant acute aortic thrombosis and pulmonary embolism complicating COVID-19 pneumonia. Diagn Interv Imaging. 2020;101:321–322. doi: 10.1016/j.diii.2020.04.003. - [DOI](#) - [PMC](#) - [PubMed](#)

3. Revel MP, Parkar AP, Prosch H et al (2020) COVID-19 patients and the radiology department – advice from the European Society of Radiology (ESR) and the European Society of Thoracic Imaging (ESTI). *Eur Radiol* 30:4903–4909 - [PMC](#) - [PubMed](#)
4. Suh YJ, Hong H, Ohana M, et al. Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis. *Radiology*. 2021;298:E70–E80. doi: 10.1148/radiol.2020203557. - [DOI](#) - [PMC](#) - [PubMed](#)
5. Jalaber C, Revel M-P, Chassagnon G, et al. Role of upfront CT pulmonary angiography at admission in COVID-19 patients. *Thromb Res*. 2020;196:138–140. doi: 10.1016/j.thromres.2020.08.037. - [DOI](#) - [PMC](#) - [PubMed](#)
6. Freund Y, Drogrey M, Miró Ò, et al. Association between pulmonary embolism and COVID-19 in emergency department patients undergoing computed tomography pulmonary angiogram: the PEPCOV International Retrospective Study. *Acad Emerg Med*. 2020;27:811–820. doi: 10.1111/acem.14096. - [DOI](#) - [PubMed](#)
7. Revel M-P, Beeker N, Porcher R, et al. What level of D-dimers can safely exclude pulmonary embolism in COVID-19 patients presenting to the emergency department? *Eur Radiol*. 2022;32:2704–2712. doi: 10.1007/s00330-021-08377-9. - [DOI](#) - [PMC](#) - [PubMed](#)
8. Stals MAM, Takada T, Kraaijpoel N, et al. Safety and efficiency of diagnostic strategies for ruling out pulmonary embolism in clinically relevant patient subgroups: a systematic review and individual-patient data meta-analysis. *Ann Intern Med*. 2022;175:244–255. doi: 10.7326/M21-2625. - [DOI](#) - [PubMed](#)
9. Wells PS, Anderson DR, Rodger M, et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. *Ann Intern Med*. 2001;135:98–107. doi: 10.7326/0003-4819-135-2-200107170-00010. - [DOI](#) - [PubMed](#)
10. Le Gal G, Righini M, Roy P-M, et al. Prediction of pulmonary embolism in the emergency department: the Revised Geneva Score. *Ann Intern Med*. 2006;144:165. doi: 10.7326/0003-4819-144-3-200602070-00004. - [DOI](#) - [PubMed](#)
11. Wang L, Yang L, Bai L, et al. Association between D-dimer level and chest CT severity score in patients with SARS-COV-2 pneumonia. *Sci Rep*. 2021;11:11636. doi: 10.1038/s41598-021-91150-1. - [DOI](#) - [PMC](#) - [PubMed](#)
12. Mestre-Gómez B, Lorente-Ramos RM, Rogado J, et al. Incidence of pulmonary embolism in non-critically ill COVID-19 patients. Predicting factors for a challenging diagnosis. *J Thromb Thrombolysis*. 2021;51:40–46. doi: 10.1007/s11239-020-02190-9. - [DOI](#) - [PMC](#) - [PubMed](#)
13. Mouhat B, Besutti M, Bouiller K, et al. Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients. *Eur Respir J*. 2020;56:2001811. doi: 10.1183/13993003.01811-2020. - [DOI](#) - [PMC](#) - [PubMed](#)
14. Hani C, Trieu NH, Saab I, et al. COVID-19 pneumonia: a review of typical CT findings and differential diagnosis. *Diagn Interv Imaging*. 2020;101:263–268. doi: 10.1016/j.diii.2020.03.014. - [DOI](#) - [PMC](#) - [PubMed](#)
15. Jalaber C, Lapotre T, Morcet-Delattre T, et al. Chest CT in COVID-19 pneumonia: a review of current knowledge. *Diagn Interv Imaging*. 2020;101:431–437. doi: 10.1016/j.diii.2020.06.001. - [DOI](#) - [PMC](#) - [PubMed](#)
16. (2020) Compte-rendu structuré de scanner thoracique pour les patients suspects de COVID-19. In: Société Fr. Radiol. <https://ebulletin.radiologie.fr/sites/ebulletin.radiologie.fr/files/medi...> Accessed 7 Jan 2021

17. van der Hulle T, Cheung WY, Kooij S, et al. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study. *Lancet*. 2017;390:289–297. doi: 10.1016/S0140-6736(17)30885-1. - [DOI](#) - [PubMed](#)
18. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Stat Med*. 1996;15:361–387. doi: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4. - [DOI](#) - [PubMed](#)
19. Musoro JZ, Zwinderman AH, Puhan MA, et al. Validation of prediction models based on lasso regression with multiply imputed data. *BMC Med Res Methodol*. 2014;14:116. doi: 10.1186/1471-2288-14-116. - [DOI](#) - [PMC](#) - [PubMed](#)
20. Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and some applications. *Stat Med*. 1991;10:585–598. doi: 10.1002/sim.4780100410. - [DOI](#) - [PubMed](#)
21. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. *Stat Med*. 2011;30:377–399. doi: 10.1002/sim.4067. - [DOI](#) - [PubMed](#)
22. Vergouwe Y, Royston P, Moons KGM, Altman DG. Development and validation of a prediction model with missing predictor data: a practical approach. *J Clin Epidemiol*. 2010;63:205–214. doi: 10.1016/j.jclinepi.2009.03.017. - [DOI](#) - [PubMed](#)
23. Lott A, Reiter JP. Wilson confidence intervals for binomial proportions with multiple imputation for missing data. *Am Stat*. 2020;74:109–115. doi: 10.1080/00031305.2018.1473796. - [DOI](#)
24. Wood AM, Royston P, White IR. The estimation and use of predictions for the assessment of model performance using large samples with multiply imputed data. *Biom J*. 2015;57:614–632. doi: 10.1002/bimj.201400004. - [DOI](#) - [PMC](#) - [PubMed](#)
25. Artifoni M, Danic G, Gautier G, et al. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. *J Thromb Thrombolysis*. 2020;50:211–216. doi: 10.1007/s11239-020-02146-z. - [DOI](#) - [PMC](#) - [PubMed](#)
26. Cau R, Pacielli A, Fatemeh H, et al. Complications in COVID-19 patients: characteristics of pulmonary embolism. *Clin Imaging*. 2021;77:244–249. doi: 10.1016/j.clinimag.2021.05.016. - [DOI](#) - [PMC](#) - [PubMed](#)
27. Galland J, Thoreau B, Delrue M, et al. White blood count, D-dimers, and ferritin levels as predictive factors of pulmonary embolism suspected upon admission in noncritically ill COVID-19 patients: the French multicenter CLOTVID retrospective study. *Eur J Haematol*. 2021;107:190–201. doi: 10.1111/ejh.13638. - [DOI](#) - [PMC](#) - [PubMed](#)
28. Ooi MWX, Rajai A, Patel R, et al. Pulmonary thromboembolic disease in COVID-19 patients on CT pulmonary angiography – prevalence, pattern of disease and relationship to D-dimer. *Eur J Radiol*. 2020;132:109336. doi: 10.1016/j.ejrad.2020.109336. - [DOI](#) - [PMC](#) - [PubMed](#)
29. Dronkers CEA, van der Hulle T, Le Gal G, et al. Towards a tailored diagnostic standard for future diagnostic studies in pulmonary embolism: communication from the SSC of the ISTH. *J Thromb Haemost*. 2017;15:1040–1043. doi: 10.1111/jth.13654. - [DOI](#) - [PubMed](#)

30. Poor HD. Pulmonary thrombosis and thromboembolism in COVID-19. *Chest*. 2021;160:1471–1480. doi: 10.1016/j.chest.2021.06.016. - [DOI](#) - [PMC](#) - [PubMed](#)
31. Jiménez D, García-Sánchez A, Rali P, et al. Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019. *Chest*. 2021;159:1182–1196. doi: 10.1016/j.chest.2020.11.005. - [DOI](#) - [PMC](#) - [PubMed](#)
32. Thoreau B, Galland J, Delrue M, et al. D-Dimer level and neutrophils count as predictive and prognostic factors of pulmonary embolism in severe non-ICU COVID-19 patients. *Viruses*. 2021;13:758. doi: 10.3390/v13050758. - [DOI](#) - [PMC](#) - [PubMed](#)
33. Fang C, Garzillo G, Batohi B, et al. Extent of pulmonary thromboembolic disease in patients with COVID-19 on CT: relationship with pulmonary parenchymal disease. *Clin Radiol*. 2020;75:780–788. doi: 10.1016/j.crad.2020.07.002. - [DOI](#) - [PMC](#) - [PubMed](#)